Pradeep Rangappa
Overview
Explore the profile of Pradeep Rangappa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
214
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suruli P, Rangappa P, Jacob I, Rao K, Shivashanker S
Cureus
. 2024 Jul;
16(6):e61690.
PMID: 38975455
Background Zinc is a trace element essential for the normal functioning of many vital enzymes and organ systems. Studies examining the rates and degrees of zinc deficiency and its consequences...
2.
Mehta Y, Mishra K, Paliwal Y, Rangappa P, Sinha S, Bhapkar S
Crit Care Res Pract
. 2023 Feb;
2022:2668199.
PMID: 36785544
Levonadifloxacin (intravenous) and its oral prodrug alalevonadifloxacin are broad-spectrum antibacterial agents developed for the treatment of difficult-to-treat infections caused by multidrug-resistant Gram-positive bacteria, especially methicillin-resistant , atypical bacteria, anaerobic bacteria,...
3.
Ashwathappa P, Jacob I, Rangappa P, Rao K
Int J Crit Illn Inj Sci
. 2023 Feb;
12(4):197-203.
PMID: 36779209
Background: Coronavirus disease 2019 (COVID-19) pneumonia with severe acute respiratory distress syndrome (ARDS) is often associated with a progressive respiratory failure that is refractory to maximal ventilatory support and other...
4.
Veeraraghavan B, Bakthavatchalam Y, Manesh A, Lal B, Swaminathan S, Ansari A, et al.
Indian J Med Microbiol
. 2022 Dec;
41:71-80.
PMID: 36509611
Background: Levonadifloxacin (intravenous) and alalevonadifloxacin (oral prodrug) are novel antibiotics based on benzoquinolizine subclass of fluoroquinolone, licensed for clinical use in India in 2019. The active moiety, levonadifloxacin, is a...
5.
Kumari S, Anand R, Sambyal B, Singh Y, Rangappa P, Jha S
J Family Med Prim Care
. 2022 Dec;
11(9):5041-5054.
PMID: 36505575
The COVID-19 pandemic has led to the development and rollout of several vaccines worldwide at unprecedented pace. This systematic review of published literature has been undertaken to spread awareness among...
6.
Rangappa P
Indian J Crit Care Med
. 2021 Dec;
25(11):1288-1291.
PMID: 34866828
How To Cite This Article: Rangappa P. Cytokine Storm and Immunomodulation in COVID-19. Indian J Crit Care Med 2021;25(11):1288-1291.
7.
Nasa P, Chaudhry D, Govil D, Daga M, Jain R, Chhallani A, et al.
Indian J Crit Care Med
. 2021 Dec;
25(11):1280-1285.
PMID: 34866826
Introduction: There is strong evidence for the use of corticosteroid in the management of severe coronavirus disease-2019 (COVID-19). However, there is still uncertainty about the timing of corticosteroids. We undertook...
8.
Kotal R, Jacob I, Rangappa P, Rao K, Hosurkar G, Anumula S, et al.
Surg Neurol Int
. 2021 Sep;
12:408.
PMID: 34513173
Background: The use of the COVID-19 vaccines Vaxzevria from AstraZeneca and Covishield from Janssen has been associated with sporadic reports of thrombosis with thrombocytopenia, a complication referred to as vaccine-induced...
9.
Nasa P, Azoulay E, Khanna A, Jain R, Gupta S, Javeri Y, et al.
Crit Care
. 2021 Mar;
25(1):106.
PMID: 33726819
Background: Coronavirus disease 2019 (COVID-19) pandemic has caused unprecedented pressure on healthcare system globally. Lack of high-quality evidence on the respiratory management of COVID-19-related acute respiratory failure (C-ARF) has resulted...
10.
Senniappan K, Jeyabalan S, Rangappa P, Kanchi M
Indian J Anaesth
. 2021 Jan;
64(10):835-841.
PMID: 33437070
The coronavirus disease 2019 (COVID-19) is a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2). Although 85% of infected patients remain asymptomatic, 5% show severe symptoms such as...